Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression.
Minaprine dihydrochloride is a novel psychotropic drug possessing both antidepressant and psycho-stimulant properties. Prior clinical studies have shown minaprine to be as effective as standard antidepressant agents in the treatment of endogenous depression. The present study examined the safety and efficacy of minaprine at four different doses compared to placebo in 190 outpatients with major depression. Overall, minaprine demonstrated a significant antidepressant action compared to placebo, which was most evident at the maximum dose of 400 mg daily. These data, together with a favorable side effects profile, suggest that minaprine may be an effective antidepressant agent for the treatment of major depression.
Amsterdam
J D
JD
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia.
Dunner
D L
DL
Fabre
L F
LF
Kiev
A
A
Rush
A J
AJ
Goodman
L I
LI
D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011724:Pyridazines / Q000009:adverse effects / Q000627:therapeutic use*
D000928:Antidepressive Agents; D011724:Pyridazines; C006149:minaprine